Figure 6. 10C8 modulates surface marker expression in PBMCs from CHB patients.

(A) MFI of cell surface markers on CD14 ⁺ cells. PBMCs from healthy donors (n = 4) or CHB patients (n = 7–8) were incubated with 10C8 at 37°C for 1 hour followed by incubation with indicated antibody and measured by flow cytometry. (B) Fold change of SIGLEC-3 and (C) CD80, CD86, MHC-I, MHC-II, CD40, PD-L1 in CD14⁺ cells of PBMCs from CHB patients or healthy donors treated with or without GS-9620. PBMCs (1 × 10⁶) from patients with CHB (n = 14–16) or healthy donors (n = 9–11) were pretreated for 1 hour with 10C8 (3 μg/mL) followed by GS-9620 treatment (10 nM and 30 nM) for another 24 hours. Cell surface markers were measured by flow cytometry. All data are expressed as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 ****P < 0.0001 (1-way ANOVA).